arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ENANTA PHARMACEUTICALS INC

ENTA
$13.77 ▲ +0.46 (+3.42%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
59 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

ENANTA PHARMACEUTICALS INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $399.9M
Dividend Yield
Revenue Growth 15.0%
Op. Margin -69.1%
ROIC -10.2%
FCF / Share $-0.25
Trailing P/E
Price / Book 3.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

59-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$17.16M
↑ +15.0%
Net Income Profit after all expenses
$-11.94M
↑ +46.4%
Operating Margin Operating profit as % of sales
-69.1%
↓ -14.3% 1th
FCF / Share Free cash flow per share
$-0.25
↑ +67.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
3
Returns
6
Financial Health
31
Cash Quality
35

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 59 quarters